Theravance Earnings Preview: Can This Streak Continue?

Theravance (NASDAQ:THRX) will report earnings after markets close on Thursday, April 25th. Theravance, Inc. is a biopharmaceutical company that discovers, develops, and markets small molecule medicines for unmet medical needs across a number of therapeutic areas including respiratory disease, bacterial infections, and gastrointestinal disorders.

Here is your Cheat Sheet to Theravance Earnings:

Earnings Expectations: Analysts expect earnings of $-0.34 per share on revenues of $5.12 million.

Analyst Trends:

Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a loss of $0.08 to a loss $0.48. For the current year, the average estimate is a loss of $2.4, which is worse than the estimate ninety days ago.

Earnings Trends:

Here’s how Theravance has been performing on an annual basis:

Fiscal Year 2008 2009 2010 2011 2012
Revenue ($) in millions 23.10 24.37 24.22 24.51 135.76
Diluted EPS ($) -1.53 -1.35 -1.16 -1.41 -0.20

Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:

Quarter Dec. 31, 2011 Mar. 31, 2012 Jun. 30, 2012 Sep. 30, 2012 Dec. 31, 2012
Revenue ($) in millions 5.36 127.10 1.43 1.43 5.80
Diluted EPS ($) -0.45 0.93 -0.42 -0.37 -0.34

Past Performance:
Theravance has beat analyst estimates 4 times in the past four quarters. Shareholders could expect a boost if the company beats estimates.

“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at]